# Apeiron Investment Group

> Apeiron Investment Group is a VC fund backing Biotechnology and Health Care. See 33 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sliema, Malta
- Total investments: 33
- Last investment: Jun 2026
- Lead investor: 45%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/apeiron-investment-group/about/
- Website: http://www.apeiron-investments.com/

Apeiron Investment Group is a VC fund in Sliema focused on Biotechnology and Health Care. Apeiron Investment Group focuses in Germany on Financial Services (especially fintech), Internet and Technology (from ecommerce to deep tech), Life Sciences, Media, Real Estate and Natural Resources. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed Seed/Start Up investments to larger scaleRestructuring and Special Situations deals (mostly listed).

## Contacts

5 contacts available for Apeiron Investment Group. Shizune tracks 2 team members at Apeiron Investment Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/apeiron-investment-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.3M–$12M |
| Series B | $30M–$91M |
| Post-IPO Equity | $722k–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 21% |
| Health Care | 6 | 18% |
| Medical | 3 | 9% |
| Biopharma | 3 | 9% |
| Life Science | 3 | 9% |

42 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 21% |
| Series B | 7 | 21% |
| Post-IPO Equity | 7 | 21% |
| Series A | 4 | 12% |
| Series C | 3 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 8 | 24% |
| United States | 4 | 12% |
| United Kingdom | 4 | 12% |
| Canada | 1 | 3% |
| Israel | 1 | 3% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jefim Gewiet | Managing Director | 0 | https://shizune.co/investors/profile/jefim-gewiet |
| Christian Angermayer | Founder & CEO | 46 | https://shizune.co/investors/profile/christian-angermayer |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enhanced Games | Enhanced Games is the contemporary reinvention of the Olympic Games without drug testing. | $50M | Post-IPO Equity | Jun 15, 2026 |  |
| Invyted | Invyted is a marketing tool that connects influencers with venues. |  | Seed | Oct 14, 2025 |  |
| Enhanced Games | Enhanced Games is the contemporary reinvention of the Olympic Games without drug testing. |  | Series B | Feb 13, 2025 |  |
| Centenara Labs | Rejuveron Life Sciences AG is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan. | $75M | Series B | Sep 10, 2023 |  |
| nextmarkets | Nextmarkets is dedicated to `helps private investors to operate in a sustainable and better educated manner on the stock exchange.For this purpose, the company developed a very easy-to-use trading platform in which private investors can trade more than 1,000 CFDs on equities , foreign exchange ( forex , FX ), bonds and commodities veryintuitively - via web and mobile apps . It is scientifically proven that more than 80 percent of all private investors fail on the stock market . This has predominantly behavioral economic reasons. | $11M | Venture - Series Unknown | Apr 18, 2023 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M | Series B | Oct 25, 2022 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M | Series B | Oct 25, 2022 |  |
| Centenara Labs | Rejuveron Life Sciences AG is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan. |  | Series B | Mar 17, 2022 |  |
| Mynaric | Mynaric specializes in manufacturing laser communication equipment designed for high-speed, long-distance wireless data transmission across various platforms, including aircraft, unmanned aerial vehicles (UAVs), high-altitude platforms (HAPs), satellites, and ground stations. Their product portfolio includes the CONDOR optical communicationsterminals (OCT) for satellites in low Earth orbit (LEO), which are capable of establishing reliable broadband connections. Additionally, Mynaric offers solutions for airborne and terrestrial applications, facilitating high data rate communication between moving objects. | $75.9M | Post-IPO Equity | Nov 12, 2021 |  |
| Cambrian Biopharma | Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is todevelop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age. | $100M | Series C | Oct 26, 2021 |  |

10 of 33 investments shown.

## Co-investors
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 9 deals together
- [Infinitas Capital](https://shizune.co/investors/profile/infinitas-capital-ag) — VC Fund, 8 deals together
- [Korify Capital](https://shizune.co/investors/profile/korify-capital) — VC Fund, 8 deals together
- [What If Ventures](https://shizune.co/investors/profile/what-if-ventures) — VC Fund, 7 deals together
- [Future Ventures](https://shizune.co/investors/profile/future-ventures) — VC Fund, 6 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Blockchain Founders Fund](https://shizune.co/investors/profile/blockchain-founders-fund) — VC Fund
- [Force Over Mass Capital](https://shizune.co/investors/profile/force-over-mass-capital) — VC Fund
- [NewBound Venture Capital](https://shizune.co/investors/profile/excelsior-financial-partners) — VC Fund

## Featured in investor lists
- [All Investors in Isle of Man](https://shizune.co/investors/investors-isle-of-man)
- [All VC Funds in Isle of Man](https://shizune.co/investors/vc-funds-isle-of-man)

## FAQ

### What does Apeiron Investment Group invest in?

Apeiron Investment Group invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series B stage. Most of the 33 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Apeiron Investment Group's check size?

Apeiron Investment Group typically joins rounds of $1.3M–$12M at Seed, $30M–$91M at Series B and $722k–$100M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Apeiron Investment Group participates in.

### How do I contact Apeiron Investment Group?

Public channels for Apeiron Investment Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Apeiron Investment Group?

The team at Apeiron Investment Group includes Jefim Gewiet (Managing Director) and Christian Angermayer (Founder & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co